| __timestamp | Exelixis, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2043000 | 72049000 |
| Thursday, January 1, 2015 | 3895000 | 110777000 |
| Friday, January 1, 2016 | 6552000 | 156328000 |
| Sunday, January 1, 2017 | 15066000 | 175820000 |
| Monday, January 1, 2018 | 26348000 | 143944000 |
| Tuesday, January 1, 2019 | 33097000 | 160152000 |
| Wednesday, January 1, 2020 | 36272000 | 188519000 |
| Friday, January 1, 2021 | 52873000 | 258234000 |
| Saturday, January 1, 2022 | 57909000 | 311103000 |
| Sunday, January 1, 2023 | 72547000 | 384447000 |
| Monday, January 1, 2024 | 0 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Exelixis, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Exelixis, Inc. saw a staggering increase in its cost of revenue, growing by over 3,400% from 2014 to 2023. In contrast, HUTCHMED's cost of revenue rose by approximately 434%, reflecting its expansive growth in the Chinese market. Notably, by 2023, HUTCHMED's cost of revenue was more than five times that of Exelixis, highlighting its larger scale of operations. This data underscores the differing growth trajectories and market strategies of these two biotech giants, offering valuable insights for potential investors.
Bristol-Myers Squibb Company vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Galapagos NV
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost of Revenue Trends: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and Evotec SE